Larimar Therapeutics (LRMR) Is Up 78.8% After Breakthrough Nod And $100M Raise Has The Bull Case Changed? [Yahoo! Finance]
Larimar Therapeutics, Inc. (LRMR)
Company Research
Source: Yahoo! Finance
Breakthrough Therapy Designation to its lead Friedreich's ataxia candidate, nomlabofusp. This combination of expedited regulatory status and fresh capital raises the company's capacity to advance nomlabofusp toward planned late-stage development and potential approval milestones. Next, we'll examine how Breakthrough Therapy Designation for nomlabofusp reshapes Larimar's investment narrative and risk profile for investors. Invest in the nuclear renaissance through our list of 84 elite nuclear energy infrastructure plays powering the global AI revolution. What Is Larimar Therapeutics' Investment Narrative? To own Larimar Therapeutics today, you have to believe that nomlabofusp can translate its current regulatory momentum into a viable first commercial product in Friedreich's ataxia, despite the company's lack of revenue and persistent losses. The FDA's Breakthrough Therapy Designation and alignment on a potential surrogate endpoint sharpen the near term focus on the planned J
Show less
Read more
Impact Snapshot
Event Time:
LRMR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LRMR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LRMR alerts
High impacting Larimar Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
LRMR
News
- Wedbush Raises its Price Target on Larimar Therapeutics (LRMR) to $13 [Yahoo! Finance]Yahoo! Finance
- Larimar Therapeutics (LRMR) was upgraded by Truist Financial Corporation to "strong-buy".MarketBeat
- Larimar Therapeutics (LRMR) had its price target raised by Wedbush from $12.00 to $13.00. They now have an "outperform" rating on the stock.MarketBeat
- Larimar Therapeutics GAAP EPS of -$0.73 misses by $0.22 [Seeking Alpha]Seeking Alpha
- Larimar Therapeutics Reports Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswire
LRMR
Earnings
- 3/19/26 - Miss
LRMR
Sec Filings
- 4/10/26 - Form PRE
- 3/19/26 - Form S-8
- 3/19/26 - Form 10-K
- LRMR's page on the SEC website